136 related articles for article (PubMed ID: 35494977)
1. Repeated Transarterial Radioembolization Adverse Event and Hepatotoxicity Profile in Cirrhotic Patients With Hepatocellular Carcinoma: A Single-Center Experience.
Reed DK; Stewart WH; Banta T; Lirette ST; Campbell GS; Patel A
Cureus; 2022 Mar; 14(3):e23578. PubMed ID: 35494977
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Radioembolization-Induced Liver Disease and Liver Toxicity Following Repeat 90Y-Radioembolization: Outcomes at a Large Tertiary Care Center.
Elsayed M; Ermentrout RM; Sethi I; Bercu ZL; Galt JR; Whitmore M; Brandon DC; Schuster DM; Kokabi N
Clin Nucl Med; 2020 Feb; 45(2):100-104. PubMed ID: 31876805
[TBL] [Abstract][Full Text] [Related]
3. Radioembolization-induced liver disease: a systematic review.
Braat MN; van Erpecum KJ; Zonnenberg BA; van den Bosch MA; Lam MG
Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):144-152. PubMed ID: 27926660
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
5. Holmium-166 Radioembolization in Hepatocellular Carcinoma: Feasibility and Safety of a New Treatment Option in Clinical Practice.
Radosa CG; Radosa JC; Grosche-Schlee S; Zöphel K; Plodeck V; Kühn JP; Kotzerke J; Hoffmann RT
Cardiovasc Intervent Radiol; 2019 Mar; 42(3):405-412. PubMed ID: 30603976
[TBL] [Abstract][Full Text] [Related]
6. Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab.
Jeschke M; Ludwig JM; Leyh C; Pabst KM; Weber M; Theysohn JM; Lange CM; Herrmann K; Schmidt HH; Jochheim LS
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686549
[TBL] [Abstract][Full Text] [Related]
7. Safety of repeated yttrium-90 radioembolization.
Lam MG; Louie JD; Iagaru AH; Goris ML; Sze DY
Cardiovasc Intervent Radiol; 2013 Oct; 36(5):1320-8. PubMed ID: 23354961
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and prevention of radioembolization-induced liver disease.
Gil-Alzugaray B; Chopitea A; Iñarrairaegui M; Bilbao JI; Rodriguez-Fraile M; Rodriguez J; Benito A; Dominguez I; D'Avola D; Herrero JI; Quiroga J; Prieto J; Sangro B
Hepatology; 2013 Mar; 57(3):1078-87. PubMed ID: 23225191
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
10. LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis.
Leyh C; Heucke N; Schotten C; Büchter M; Bechmann LP; Wichert M; Dechêne A; Herrmann K; Heider D; Sydor S; Lemmer P; Ludwig JM; Pospiech J; Theysohn J; Damm R; March C; Powerski M; Pech M; Özcürümez M; Weigt J; Keitel V; Lange CM; Schmidt H; Canbay A; Best J; Gerken G; Manka PP
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230506
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
Kambhampati S; Bauer KE; Bracci PM; Keenan BP; Behr SC; Gordan JD; Kelley RK
Cancer; 2019 Sep; 125(18):3234-3241. PubMed ID: 31154669
[TBL] [Abstract][Full Text] [Related]
12. Safety of Radioembolization in the Setting of Angiographically Apparent Arterioportal Shunting.
Thornton LM; Geller BS; Pepin EW; Shah JL; Kapp M; Toskich BB
J Vasc Interv Radiol; 2018 Nov; 29(11):1511-1518. PubMed ID: 30293727
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory.
Badar W; Van Ha T; Zangan S; Navuluri R; Pillai A; Baker T; Dalag L; Han R; Ahmed O
Br J Radiol; 2021 Mar; 94(1119):20200752. PubMed ID: 33411569
[TBL] [Abstract][Full Text] [Related]
14. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
15. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
[TBL] [Abstract][Full Text] [Related]
16. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.
Garwood ER; Fidelman N; Hoch SE; Kerlan RK; Yao FY
Liver Transpl; 2013 Feb; 19(2):164-73. PubMed ID: 23008091
[TBL] [Abstract][Full Text] [Related]
17. ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma.
Lescure C; Estrade F; Pedrono M; Campillo-Gimenez B; Le Sourd S; Pracht M; Palard X; Bourien H; Muzellec L; Uguen T; Rolland Y; Garin E; Edeline J
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359695
[TBL] [Abstract][Full Text] [Related]
18. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy.
Lam MG; Abdelmaksoud MH; Chang DT; Eclov NC; Chung MP; Koong AC; Louie JD; Sze DY
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):323-9. PubMed ID: 23849697
[TBL] [Abstract][Full Text] [Related]
19. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Zu Q; Schenning RC; Jahangiri Y; Tomozawa Y; Kolbeck KJ; Kaufman JA; Al-Hakim R; Naugler WE; Nabavizadeh N; Kardosh A; Billingsley KG; Mayo SC; Orloff SL; Enestvedt KK; Maynard E; Ahn J; Lhewa D; Farsad K
Cardiovasc Intervent Radiol; 2020 May; 43(5):721-731. PubMed ID: 32140840
[TBL] [Abstract][Full Text] [Related]
20. Improved survival following transarterial radioembolization of infiltrative-appearance hepatocellular carcinoma.
Nisiewicz MJ; Kapoor H; Fowler KJ; Furlan A; Dugan AJ; Owen JW
Abdom Radiol (NY); 2021 May; 46(5):1958-1966. PubMed ID: 33385248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
